Holen Sie sich die Stockscreener-App
1.60
3.23%
0.05
Vorhandelsmarkt:
1.59
-0.01
-0.63%
Schlusskurs vom Vortag:
$1.55
Offen:
$1.57
24-Stunden-Volumen:
1.67M
Relative Volume:
1.83
Marktkapitalisierung:
$79.49M
Einnahmen:
$300.00K
Nettoeinkommen (Verlust:
$-27.61M
KGV:
-2.7696
EPS:
-0.5777
Netto-Cashflow:
$-22.17M
1W Leistung:
-5.88%
1M Leistung:
+8.84%
6M Leistung:
-15.34%
1J Leistung:
+96.37%
1-Tages-Spanne:
$1.48
$1.63
1-Wochen-Bereich:
$1.48
$1.76
52-Wochen-Spanne:
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
Firmenname
iBio Inc
Sektor
Branche
Telefon
302-355-0650
Adresse
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.60 | 81.97M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-05-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-11-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-01-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Eingeleitet | Alliance Global Partners | Buy |
Alle ansehen
iBio Inc Aktie (IBIO) Neueste Nachrichten
Top iBio (IBIO) Competitors 2026 - MarketBeat
Could iBio (IBIO) Be an Underrated Obesity Stock? - Insider Monkey
5 Under-the-Radar AI Stocks to Buy in 2026 - Insider Monkey
iBio Inc. (IBIO) Nears Key Support Amid Slight Decline: Technical AnalysisQuote Data - newsline.com
IBIO Initiates Coverage On Raymond James -- Rating Set to Outper - GuruFocus
IBIO Initiates Coverage On Raymond James -- Rating Set to Outperform - GuruFocus
Raymond James initiates iBio stock coverage with outperform rating By Investing.com - Investing.com South Africa
Raymond James Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $5 - Moomoo
Raymond James initiates iBio stock coverage with outperform rating - Investing.com
B. Riley Initiates IBio at Buy With $6 Price Target - Moomoo
IBIO: Advancing antibody-based therapies for obesity, muscle preservation, and weight maintenance - TradingView
IBIO: Advancing antibody-based therapies for obesity and weight maintenance with key clinical milestones ahead - TradingView
iBio to Participate in Upcoming Healthcare Investor Conferences - The Manila Times
AI drug developer iBio joins two health investor events in June and July 2026 - Stock Titan
iBio doses first patient in obesity drug trial - Investing.com UK
iBio (IBIO) Begins Phase 1 Clinical Trial for IBIO-600 - GuruFocus
iBio doses first patient in obesity drug trial By Investing.com - Investing.com Australia
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity - The Manila Times
iBio tests long-acting obesity antibody designed to preserve muscle - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $6 - 富途牛牛
IBIO - Finviz
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
$IBIO stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
iBio (IBIO) director receives 60,000 stock options vesting over 3 years - Stock Titan
LifeSci Capital Remains a Buy on Ibio (IBIO) - The Globe and Mail
Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO) - The Globe and Mail
Logos Global reports zero ownership in iBio (NASDAQ: IBIO) - Stock Titan
Point72, Steven A. Cohen report 0% in iBio (IBIO) amendment - Stock Titan
EcoR1 and Oleg Nodelman report 1.58M shares in iBio (NASDAQ: IBIO) - Stock Titan
Cormorant (IBIO) reports 3.83M shares, holds near-10% via warrants - Stock Titan
iBio (NASDAQ: IBIO) — Sirenia/Manager report 11.59M shares, near 10% cap - Stock Titan
Elizabeth Stoner joins iBio (IBIO) board and files initial Form 3 - Stock Titan
We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate - Yahoo Finance
iBio (IBIO) adviser and manager report a 9.99% beneficial stake - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Insider Traders Lose US$19k As iBio Drops - simplywall.st
iBio, Inc. Stock 12‑Month Price Target Raised to $5.53, Implies 244% Upside - TradingView
IBio 3Q Rev $0.00 >IBIO - Moomoo
Intelligent Bio Solutions Reports 46% Revenue Growth in Q3 FY202 - GuruFocus
IBIO Achieves Key Milestones in Obesity Treatment Development - GuruFocus
IBio 3Q Loss $7.73M >IBIO - Moomoo
IBio reports Q3 fiscal year 2026 financial results and provides corporate update - marketscreener.com
iBio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Frazier funds disclose holdings and warrants in iBio (NASDAQ: IBIO) - Stock Titan
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Finanzdaten der iBio Inc-Aktie (IBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):